Evidence map›Paper›PMID 41861016›Full record

ArticleScience advances2026

Photothermal catalysis versus thermal catalysis: A palladium-catalyzed intermolecular three-component C─H 1,3-

He-Yuan Bai, Kai Tang, Zi-Hao Li, Xiangyang Chen, Shu-Yu Zhang

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Science advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

He-Yuan BaiState Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0000-0002-8986-6913
Kai TangFrontiers Science Center for Transformative Molecules, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai, 200240, China.ORCID 0009-0009-2344-7626
Zi-Hao LiState Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.
Xiangyang ChenFrontiers Science Center for Transformative Molecules, State Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai, 200240, China.ORCID 0000-0002-6981-7022
Shu-Yu ZhangState Key Laboratory of Synergistic Chem-Bio Synthesis, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, School of Chemistry and Chemical Engineering, Shanghai Jiao Tong University, Shanghai 200240, China.ORCID 0000-0002-1811-4159

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Although transition metal-catalyzed C─H activation has notably advanced C─H functionalization, achieving highly selective C─H difunctionalization remains a substantial challenge. Current C─H difunctionalization strategies remain largely constrained to two-component annulation reactions or dicarbofunctionalization, which inherently limit structural diversity and synthetic efficiency. Here, we report a palladium-catalyzed three-component C─H 1,3-

Identifiers

PMID41861016
PMCPMC13150648

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.